Loading Page
Dr. Darrell J. Yamashiro, MD is a physician provider in New York, NY specializing in physician, general pediatrics and pediatric hematology/oncology. He graduated from New York University (NYU) School of Medicine in 1989 and has 37 years of experience. Dr. Darrell J. Yamashiro, MD is affiliated with NewYork-Presbyterian, ColumbiaDoctors, Columbia University Irving Medical Center and CUIMC/Herbert Irving Pavilion.
Dr. Darrell J. Yamashiro, MD graduated from New York University (NYU) School of Medicine in 1989. He completed residency at The Children's Hospital of Philadelphia. He is certified by the Board Certification: pediatrics and has a state license in New York.
Medical School: New York University (NYU) School of Medicine (1989)
Residency: The Children's Hospital of Philadelphia
Board Certification: Board Certification: pediatrics
Licensed In: New York
Dr. Darrell J. Yamashiro, MD appears to accept the following insurance providers: VNSNY CHOICE, CIGNA, Healthspring (Cigna Medicare), Local 1199, Empire Blue Cross/Blue Shield, Emblem/GHI, ElderServe, Medicare, Affinity Health Plan, Amida Care, UnitedHealthcare, Empire Blue Cross Blue Shield Healthplus, Emblem/Hip, Fidelis Care, MVP Health Care, WellCare, World Trade Center Health Plan, Magnacare (National), AETNA, Multiplan, Healthfirst, MultiPlan, United Healthcare PPO, United Healthcare POS, United Healthcare HMO, Aetna POS, MVP Health Care, MagnaCare, Vytra, Great-West Healthcare, Healthfirst, Aetna EPO, Aetna PPO, Aetna HMO, GHI PPO, Group Health Incorporated (GHI), CIGNA PPO, Aetna Signature Administrators, CIGNA POS, CIGNA HMO, CIGNA EPO, EmblemHealth, WellCare, Medicaid Managed Care, Blue Shield PPO, Blue Shield HMO, Blue Shield EPO, HealthSpring, UnitedHealthcare, Affinity Health Plan, United Healthcare, Medicare, Medicaid, Railroad Medicare, Cigna, 1199SEIU, Oxford HMO, Fidelis Care, HIP PPO, HIP POS, HIP EPO, HIP HMO, Empire BlueCross BlueShield HMO, Empire BlueCross BlueShield PPO, Empire BlueCross BlueShield, Aetna, Healthfirst - Leaf (Exchange), ElderServe - Special Needs, AETNA - Student Health, MVP Health Care - Child/Family Health Plus, Healthfirst - Child/Family Health Plus, Empire Blue Cross - EPO, AETNA - NY Signature, Amida Care - Special Needs, AETNA - Medicare Managed Care, Healthfirst - Medicare Managed Care, VNSNY CHOICE - SelectHealth, VNSNY CHOICE - Medicare Managed Care, MVP Health Care - Essential Plan, World Trade Center Health Plan - World Trade Center Health Plan, Medicare - Traditional Medicare, VNSNY CHOICE - Special Needs and MVP Health Care - HMO.
According to our sources, Dr. Darrell J. Yamashiro, MD accepts the following insurance providers:
Dr. Darrell J. Yamashiro, MD does not have any reviews yet, be the first to leave a review of Dr. Darrell J. Yamashiro, MD here: Leave a Review
These charts describe general payments received by Dr. Darrell J. Yamashiro, MD. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
|
$5,400
ZALTRAP $5,400 |
|
|
$46
AFINITOR $46 |
| $5,400 | |
| $46 |
Dr. Darrell J. Yamashiro, MD has received 2 research payments totaling $305.
I am a pediatric oncologist who specializes in caring for children with solid tumors, especially neuroblastoma, Wilms' and other kidney tumors, and liver tumors such hepatoblastoma and hepatocellular carcinoma. I serve as chief of the Division of Hematology, Oncology and Stem Cell Transplantation at Columbia University Irving Medical Center and NewYork-Presbyterian Morgan Stanley Children's Hospital. I treat children of all ages, from infants to young adults. Some of the cancers I treat are rare (liver tumors account for one to two percent of childhood cancers), but they can be very complex and require a multidisciplinary approach so patients have the best outcomes. I enjoy working as part of a team of physicians, nurse practitioners, nurses, social workers, child life specialists, and other dedicated professionals who care deeply about our patients and provide care with compassion and comfort. I also conduct basic science research. The latest advances in tumor genetics and the design of innovative therapies make this a very exciting time for cancer research. My team and I have done extensive research on the genetics of hepatoblastoma. We have developed mouse models of this disease and are entering a new phase where we are offering a personalized/precision medicine approach to children with this disease. We are also identifying novel genes that specifically target neuroblastoma—information that may be used to create targeted therapies.
